Mesane Tümörlerinin Genel Özellikleri

Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

Babjuk M, Burger M, Compérat EM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. Eur Urol. 2019;76(5):639-57.

Kara F, Keskinkılıç B. Türkiye Kanser İstatistikleri 2016. Ankara: Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü; 2019.

Hinotsu S, Akaza H, Miki T, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009;16(1):64-9.

Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(S1):316-29.

Freedman ND, Abnet CC, Caporaso NE, et al. Impact of changing US cigarette smoking patterns on incident cancer: risks of 20 smoking-related cancers among the women and men of the NIH-AARP cohort. Int J Epidemiol. 2016;45(3):846-56.

Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11(18):6512-9.

Barrett JC, Wiseman RW. Cellular and molecular mechanisms of multistep carcinogenesis: relevance to carcinogen risk assessment. Environ Health Perspect. 1987;76:65-70.

Oliveira PA, Colaço A, Chaves R, et al. Chemical carcinogenesis. An. Acad. Bras. Ciênc. 2007;79(4):593-616.

Reznikoff CA, Kao C, Messing EM, et al. A molecular genetic model of human bladder carcinogenesis. Semin Cancer Biol. 1993;4(3):143-52.

Steineck G, Plato N, Norell SE, et al. Urothelial cancer and some industry‐related chemicals: An evaluation of the epidemiologic literature. Am J Ind Med. 1990;17(3):371-91.

Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8(3):346-55.

Cumberbatch MG, Rota M, Catto JW, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016;70(3):458-66.

Hecht SS. Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006;391(6):603-13.

Reis LO, Pereira TC, Favaro WJ, et al. Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol. 2009;27(3):353-61.

Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737-45.

Pietzak EJ, Mucksavage P, Guzzo TJ, et al. Heavy cigarette smoking and aggressive bladder cancer at initial presentation. Urology. 2015;86(5):968-73.

Jiang X, Yuan J-M, Skipper PL, et al. Environmental tobacco smoke and bladder cancer risk in never smokers of Los Angeles County. Cancer Res. 2007;67(15):7540-5.

Kogevinas M, Mannetje At, Cordier S, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control. 2003;14(10):907-14.

Smailyte G, Kurtinaitis J, Andersen A. Mortality and cancer incidence among Lithuanian cement producing workers. Occup Environ Med. 2004;61(6):529-34.

LeMasters GK, Genaidy AM, Succop P, et al. Cancer risk among firefighters: a review and meta-analysis of 32 studies. J Occup Environ Med. 2006;48(11):1189-202.

Youakim S. Risk of cancer among firefighters: a quantitative review of selected malignancies. Arch Environ Occup Health. 2006;61(5):223-31.

Zeegers M, Swaen G, Kant I, et al. Occupational risk factors for male bladder cancer: results from a population based case cohort study in the Netherlands. Occup Environ Med. 2001;58(9):590-6.

Ames BN, Kammen H, Yamasaki E. Hair dyes are mutagenic: identification of a variety of mutagenic ingredients. Proc Natl Acad Sci U S A. 1975;72(6):2423-7.

Gago‐Dominguez M, Castelao JE, Yuan JM, et al. Use of permanent hair dyes and bladder‐cancer risk. Int J Cancer. 2001;91(4):575-9.

McDougal WS, Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology 11th Edition Review E-Book: Elsevier Health Sciences; 2015.

Villanueva CM, Fernandez F, Malats N, et al. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J Epidemiol Community Health. 2003;57(3):166-73.

Smith AH, Marshall G, Roh T, et al. Lung, bladder, and kidney cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241-9.

Michaud DS, Spiegelman D, Clinton SK, et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med. 1999;340(18):1390-7.

Daneshmand S. Epidemiology and risk factors of urothelial (transitional cell) carcinoma of the bladder 2020 [updated Mar 12, 2020; cited 2020]. Available from: https://www.uptodate.com/contents/epidemiology-and-risk-factors-of-urothelial-transitional-cell-carcinoma-of-the-bladder?source=history_widget.

Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis. 2011;204(2):217-23.

Matsui Y, Utsunomiya N, Ichioka K, et al. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology. 2005;65(2):279-83.

Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol. 2020,24;S0302-2838(20)30427-9.

Castellan M, Gosalbez R, Perez-Brayfield M, et al. Tumor in bladder reservoir after gastrocystoplasty. J Urol. 2007;178(4S):1771-4.

Soergel TM, Cain MP, Misseri R, et al. Transitional cell carcinoma of the bladder following augmentation cystoplasty for the neuropathic bladder. J Urol. 2004;172(4 Part 2):1649-52.

Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477-84.

Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995;87(7):524-31.

Habs MR, Schmáhl D. Prevention of urinary bladder tumors in cyclophosphamide‐treated rats by additional medication with the uroprotectors sodium 2‐mercaptoethane sulfonate (mesna) and disodium 2, 2′‐dithio‐bis‐ethane sulfonate (dimesna). Cancer. 1983;51(4):606-9.

Lin J, Spitz MR, Dinney CP, et al. Bladder cancer risk as modified by family history and smoking. Cancer. 2006;107(4):705-11.

Carlo MI, Ravichandran V, Srinavasan P, et al. Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol. 2020;38(5):406-14.

Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62(3):809-18.

Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252(5006):706-9.

Malats N, Bustos A, Nascimento CM, et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678-86.

Cordon-Cardo C, Wartinger D, Petrylak D, et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst. 1992;84(16):1251-6.

Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014-24.

Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;25(11):1649-58.

Okkels H, Sigsgaard T, Wolf H, et al. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev. 1997;6(4):225-31.

Bell DA, Taylor JA, Paulson DF, et al. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85(14):1159-64.

García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366(9486):649-59.

Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6):4-34.

Lopez-Beltran A. Bladder cancer: clinical and pathological profile. Scand J Urol Nephrol Suppl. 2008;42(sup218):95-109.